News
AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.
ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.
The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.
MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.
Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.
Verastem has reported primary analysis data from the Phase II RAMP 201 trial, where the avutometinib combination showed an ORR of 31% ...
Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their ...
Crinetics Pharmaceuticals has revealed new data from its clinical development programme for Palsonify, an oral treatment for acromegaly.
XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.
UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.
Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have showed NeoVaxMI's improved immune response in melanoma patients.
A panel at CTO East Coast discussed the regulatory changes impacting oncology trials and how these can be managed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results